stockrowHaemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.
- Revenue
- +9.30%
- EPS
- +25.9%
- Free cash flow
- +20.4%
- Total debt
- +21.0%
Quarter to September 2026, against a year earlier
Follow HAE
Alert me
Haemonetics Corporation (HAE) Operating cash flow
Haemonetics Corporation's operating cash flow for fiscal 2026 was $293.2M, up 61.4% from $181.7M in fiscal 2025. Over the twelve months to 30 September 2026 it was $344.9M. Over the past ten years it has ranged from $108.8M (fiscal 2021) to $293.2M (fiscal 2026) — the current reading is the highest in ten years. Haemonetics Corporation ranks 17th of 149 Medical Devices companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2026 | $293.2M | 61.35% |
| FY2025 | $181.7M | (0.01%) |
| FY2024 | $181.8M | (33.44%) |
| FY2023 | $273.1M | 58.51% |
| FY2022 | $172.3M | 58.32% |
| FY2021 | $108.8M | (31.23%) |
| FY2020 | $158.2M | (0.67%) |
| FY2019 | $159.3M | (27.71%) |
| FY2018 | $220.4M | 37.94% |
| FY2017 | $159.7M | 31.08% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $128.1M | 144.83% |
| Jun 2026 | $52.3M | (26.24%) |
| Mar 2026 | $70.9M | (24.18%) |
| Dec 2025 | $93.6M | (15.95%) |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| BIO.B Bio-Rad Laboratories, Inc. compare | $468.1M |
| BIO Bio-Rad Laboratories, Inc. compare | $468.1M |
| HAE Haemonetics Corporation | $344.9M |
| BRKR Bruker Corporation compare | $341.8M |
| LIVN LivaNova PLC compare | $237.9M |
| ITGR Integer Holdings Corporation compare | $176.5M |
| TXG 10x Genomics compare | $127.1M |
| IRTC iRhythm Holdings, Inc. compare | $55.6M |
| AXGN AxoGen, Inc. compare | $28.4M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on HAE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement